The FDA approved Simtriyo (centanafadine), Otsuka's once-daily extended-release capsule for attention deficit hyperactivity disorder, on July 24, 2026, per an announcement the company made on July 27. The drug is cleared for adults and for children aged 6 and older.
Newspaper Daily publishes information, not medical advice. The outlet reports on regulatory actions and research findings and does not provide diagnosis or treatment guidance.
A new mechanism in a crowded field
Most ADHD medications raise norepinephrine and dopamine signaling; stimulants add effects that carry misuse potential, and non-stimulants act more slowly. Centanafadine is described by Otsuka as the first approved norepinephrine, dopamine, and serotonin reuptake inhibitor, or NDSRI, meaning it modulates all three systems. The application received priority review, under which the agency commits to a faster decision timeline.
Trial details cited in coverage of the decision showed symptom improvements versus placebo, though the company had not published full results in a journal at the time of approval.
Related stories: FDA Approves First Oral Antiviral to Prevent COVID-19 After Exposure · FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol.
What this approval can and cannot show
Attention deficit hyperactivity disorder affects millions of children and adults in the United States, and prescriptions for its treatment have grown steadily over the past decade, per federal survey estimates.
Approval means the regulator judged the efficacy and safety evidence adequate for the ADHD indication. It does not establish how the drug compares with established stimulants and non-stimulants in head-to-head trials, which patients will respond best, or its long-term growth and cardiovascular profile in children, questions that extend beyond registration trials. Otsuka had not announced launch timing or pricing as of its July 27 statement. Because registration trials excluded some groups, including patients with certain cardiac histories, real-world safety monitoring will matter as prescriptions begin.
When to talk to a clinician
ADHD treatment decisions should weigh symptom profile, coexisting conditions, cardiac history, and prior medication responses. Availability is expected to follow after manufacturing and distribution begin, so patients should not expect the new option to be in pharmacies immediately.